What Happened?

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Drug Development Inputs & Services company Medpace (NASDAQ: MEDP) fell 3.4%. Is now the time to buy Medpace? Access our full analysis report here, it’s free.
• Research Tools & Consumables company Revvity (NYSE: RVTY) fell 2.9%. Is now the time to buy Revvity? Access our full analysis report here, it’s free.
• Drug Development Inputs & Services company Azenta (NASDAQ: AZTA) fell 3.7%. Is now the time to buy Azenta? Access our full analysis report here, it’s free.
• Research Tools & Consumables company Bio-Techne (NASDAQ: TECH) fell 4.4%. Is now the time to buy Bio-Techne? Access our full analysis report here, it’s free.
• Health Insurance Providers company Oscar Health (NYSE: OSCR) fell 3.2%. Is now the time to buy Oscar Health? Access our full analysis report here, it’s free.

Zooming In On Bio-Techne (TECH)

Bio-Techne’s shares are very volatile and have had 21 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 10 months ago when the stock gained 7.8% on the news that the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement has cooled fears of a prolonged trade war, helping stabilize expectations for global growth and trade flows and fueling renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand.

Bio-Techne is down 7.8% since the beginning of the year, and at $55.00 per share, it is trading 22.9% below its 52-week high of $71.38 from January 2026. Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago would now be looking at an investment worth $583.73.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free.